Clinical Trial

A Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1982 to Prevent Lyme Disease in Healthy Participants (18 to 70 Years of Age)

Active, Not Recruiting Phase 2
View on ClinicalTrials.gov →
Summary
This clinical study will evaluate the safety, reactogenicity, and immunogenicity of monovalent mRNA-1982, a messenger ribonucleic acid (mRNA) vaccine to prevent Lyme disease in healthy adults aged 18 to 70 years old.
Protocol Amendment History 2 changes
critical Enrollment closed, study ongoing 2026-08-04
critical Recruitment opened 2026-05-12
Trial Details
NCT Number NCT07561294
Lead Sponsor ModernaTX, Inc.
Conditions Lyme Disease
Enrollment 366 participants
Start Date 2026-04-29
Primary Completion 2028-11-09 (estimated)
Study Completion 2028-11-09 (estimated)
Updated on ClinicalTrials.gov 2026-08-03